# FDA and EMA's 10 Principles for AI in Drug Development: Practical Takeaways for Sponsors and Partners

> FDA and EMA issued 10 AI principles for drug development, emphasizing reliable, auditable evidence and patient safety. Expect risk-based design, traceability, and human oversight.

- Type: AI news
- Page: https://completeaitraining.com/news/fda-and-emas-10-principles-for-ai-in-drug-development/
- Published: 2026-01-24
- Updated: 2026-02-19
- Author: Jeroen Erne
- Jobs: IT and development
- Reading time: 3 min

### Model Behavior: FDA and EMA's Guide to Good AI in Drug Development

On January 23, 2026, the FDA and EMA released a joint statement with 10 guiding principles for using AI across drug development. This isn't a new rulebook. It's a clear signal: if AI supports any regulated work, your evidence must be reliable, auditable, and safe for patients.

These principles apply to sponsors, CROs/CMOs, software teams, data vendors, and anyone building, validating, or operating AI that feeds into non-clinical research, clinical trials, manufacturing, or post-market safety. The term "drug" includes drugs, biologics, and EU medicinal products.

#### What was released

The agencies outlined how AI should be designed, tested, governed, and communicated when it generates or analyzes evidence used in regulatory decisions. AI is defined broadly: systems that support research, trials, production, and safety monitoring.

Bottom line: AI should support-not weaken-core requirements for quality, efficacy, and safety. The focus is reliability of evidence and protections for patients.

#### Why this matters for your FDA/EMA interactions

- Be ready to explain data lineage, preprocessing steps, and why the model is fit for its stated purpose.
- Expect questions on human oversight, cybersecurity, access control, monitoring for drift, and change control.
- Early alignment with these principles reduces rework, speeds review, and improves inspection readiness.

#### The 10 principles in plain language (grouped by theme)

- **Human-centric by design (#1):** Build for patient and user safety from day one. Anticipate impacts and bake in safeguards.
- **Risk-based approach (#2):** Define context-of-use. Scale testing, controls, and oversight to the level of risk. High-impact decisions need deeper validation.
- **Adherence to standards (#3) + Multidisciplinary expertise (#5):** Follow legal, ethical, technical, scientific, cybersecurity, and regulatory standards (e.g., GxP). Involve domain experts, data scientists, software engineers, security, clinical/manufacturing quality, and safety teams.
- **Clear context, data governance, model practice (#4, #6, #7):** Document sources, transformations, and analytical choices with traceability and privacy controls. Use data that fits the purpose. Balance interpretability, explainability, and predictive performance with safety in mind.
- **Risk-based performance, lifecycle management, clear information (#8, #9, #10):** Validate the full system (people + process + tech). Govern the lifecycle with a QMS. Monitor, re-evaluate, and communicate purpose, performance, limits, data used, update cadence, and how to interpret outputs-in plain language.

#### What IT and Development teams should do now

- **Define context-of-use:** Who uses it, where in the workflow, what decisions it influences, and acceptable limits.
- **Set a risk taxonomy:** Categorize AI uses by impact; tie controls and validation depth to risk.
- **Tight data governance:** Data lineage, consent and privacy controls, versioning, and access logging. Keep it traceable and verifiable.
- **MLOps with guardrails:** Reproducible training pipelines, model registries, environment parity, and immutable artifacts.
- **Validation plan:** Prespecified metrics, thresholds, and acceptance criteria that match the context-of-use. Use representative, independent datasets.
- **Human-in-the-loop design:** Clear escalation paths, override options, and operator training.
- **Security-first:** Threat modeling, secure software lifecycle, dependency hygiene, secrets management, and audit trails.
- **Monitoring and alerts:** Drift detection, performance decay tracking, data quality checks, and rollback procedures.
- **Change control:** Documented updates, impact assessments, re-validation triggers, and versioned release notes.
- **Transparent comms:** Plain-language model cards and user guidance that state purpose, limits, data used, and how to interpret outputs.
- **Vendor oversight:** Contracts with audit rights, evidence requirements, SLAs for incidents, and security/privacy expectations.

#### How this fits with existing FDA/EMA expectations

- **Data integrity:** Traceability and auditability echo ALCOA+ principles.
- **Validation:** "Fit for intended use" mirrors current clinical and manufacturing review practices.
- **Quality systems:** Lifecycle governance matches GCP/GMP expectations, including deviations and periodic review.
- **Security & privacy:** Aligns with existing requirements to protect systems and sensitive data.

You don't need new processes-extend your QMS, CSV/CSA, and risk management to cover AI systems and their data pipelines.

#### Artifacts regulators may ask for

- Context-of-use statement and risk classification.
- Data inventory, lineage, and governance controls.
- Model card, training/eval datasets description, and rationale for metrics.
- Validation protocol/report with predefined acceptance criteria.
- Human factors/usability evidence for AI-assisted workflows.
- Security risk assessment, access logs, and incident response plan.
- Monitoring plan, drift thresholds, and re-validation triggers.
- Change control records and version history.

#### Common pitfalls to avoid

- Vague context-of-use; unclear decision boundaries or users.
- Validating the model but not the end-to-end system and workflow.
- Skipping human oversight or operator training.
- No plan for drift, dataset shift, or degraded performance.
- Weak vendor controls or missing audit rights.
- Unexplained outputs with no error bounds or confidence guidance.

#### Useful resources

- [NIST AI Risk Management Framework](https://www.nist.gov/itl/ai-risk-management-framework?ref=completeaitraining.com)
- [ICH Guidelines (GCP, GMP, and related)](https://www.ich.org/page/ich-guidelines?ref=completeaitraining.com)

#### Skill up your team

If you're building or validating AI for regulated use, targeted upskilling shortens the path from prototype to compliant production.

- [AI Learning Path for Regulatory Affairs Specialists](https://completeaitraining.com/learningpath/ai-for-regulatory-affairs-specialists/) \- focused on regulatory expectations, validation, and data governance.
- [AI Learning Path for CIOs](https://completeaitraining.com/learningpath/ai-for-cios-chief-information-officers/) \- covers governance, security, and lifecycle management.
- [AI Learning Path for Project Managers](https://completeaitraining.com/learningpath/ai-for-project-managers/) \- practical guidance for coordinating AI-enabled regulated projects.

The takeaway: treat AI like any other regulated system-clear purpose, sound data, fit-for-use validation, lifecycle controls, and honest communication. Do that, and your AI can stand up to scrutiny across the drug lifecycle.

---

This is the Markdown form of https://completeaitraining.com/news/fda-and-emas-10-principles-for-ai-in-drug-development/. The whole site is mapped at https://completeaitraining.com/llms.txt.
